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Toxic tau oligomer formation blocked by capping
of cysteine residues with 1,2-dihydroxybenzene
groups
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Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological
hallmark of Alzheimer’s disease; the neurofibrillary tangle load correlates strongly with
clinical progression of the disease. A growing body of evidence indicates that tau
oligomer formation precedes the appearance of neurofibrillary tangles and contributes to
neuronal loss. Here we show that tau oligomer formation can be inhibited by compounds
whose chemical backbone includes 1,2-dihydroxybenzene. Specifically, we demonstrate that
1,2-dihydroxybenzene-containing compounds bind to and cap cysteine residues of tau and
prevent its aggregation by hindering interactions between tau molecules. Further, we show
that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton
includes 1,2-dihydroxybenzene and which penetrates the brain, reduces the levels of
detergent-insoluble tau, neuronal loss and reverses neurofibrillary tangle-associated brain
dysfunction. Thus, compounds that target the cysteine residues of tau may prove useful in
halting the progression of Alzheimer’s disease and other tauopathies.
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A
lzheimer’s disease (AD) is a progressive neurodegenera-
tive disease, initially characterized by impaired episodic
memory and eventually, severe cognitive decline. Since
age is the most important risk factor for AD development, the
present increase in lifespan across all demographics prioritizes
the search for ameliorative and preventative treatments for
the disease. Currently, cholinesterase inhibitors and N-methyl-D-
aspartate receptor antagonists are used to treat AD symptoms
with limited success; the current consensus view is that
stopping disease progression will require the development of
disease-modifying therapies based on defined pathogenic
mechanisms1.
Deposition of amyloid b (Ab) peptide in the extracellular space
and formation of senile plaques, as well as the intracellular
accumulation of tau protein that gives rise to neurofibrillary
tangles (NFTs), with contemporaneous neuronal loss are the key
pathological hallmarks of AD2. The amyloid hypothesis of AD
posits that Ab is the primary cause of dementia owing to its
ability to induce the formation of NFT and synaptic and neuronal
loss in the neocortex3–7. Tau tangle formation occurs
downstream from Ab deposition and appears to be essential for
the establishment of AD; the latter view is supported by studies
showing that tau depletion prevents Ab-induced memory
impairment in various lines of human amyloid precursor
protein-overexpressing mice8,9.
To date, Ab-targeted therapies (for example, immunotherapy)
have failed for a variety of reasons, including failure to hamper
neurodegeneration and cognitive dysfunction in patients with
AD10,11. The focus of AD drug discovery research has recently
shifted towards tau12 because, in contrast to Ab load, tau
pathology correlates with the degree of cognitive impairment13,14
and neuronal loss15,16. Tau is an attractive target because patients
with frontotemporal dementia and Parkinsonism-linked to
chromosome-17 (FTDP-17) carry a mutation in the tau gene
and display NFT and neuronal loss in the absence of Ab
deposition17–19. Moreover, mice overexpressing mutant tau
exhibit NFTs, neuronal loss and behavioural abnormalities20–24.
Several lines of evidence, based on the results of experiments
involving expression of the human P301L transgene in mice25,26
or the human FTDP17 mutation in fruit flies27, link neuronal
death to the tau aggregation process, rather than to NFT
formation.
Tau protein in NFTs is highly phosphorylayed, reflecting
an imbalance in the activities of various kinases and
phosphatases28,29. Although the role of phosphorylation in the
Tau aggregation process is still debated (for example, in vitro
evidence suggests Tau phosphorylation inhibits30 or has no role
on tau aggregation31), hyperphosphorylated and/or mutated tau
is suggested to adopt an alternative structure that promotes
interactions between individual tau molecules. For example, our
own in vitro experiments have proposed that tau aggregation
occurs in a step-wise manner: initially, tau molecules bind to each
other, through disulfide binding of their Cys residues32, to form
soluble tau oligomers32,33; in a second step, these oligomers,
comprised of B40 tau molecules, grow and precipitate as
granular tau oligomers with a b-sheet structure; last, the
granular tau oligomers bind to each other and form tau fibrils33.
Granular tau oligomers are detectable in the prefrontal cortex
at Braak stage I, whereas NFT appear much later (Braak stage
V)34, indicating that their formation represents a crucial early
pathogenic event. Observations that neuronal death is strongly
associated with the presence of Sarkosyl-insoluble tau26, imply
that granular tau oligomers with a b-sheet structure are a major
toxic species of tau and that prevention of their formation could
be a promising therapeutic strategy35. Following this rationale, we
screened a small-molecule library for compounds with the
potential to inhibit the formation of granular tau oligomers. We
report here that compounds containing 1,2-dihydroxybenzene
inhibit granular tau oligomer formation by modifying the
Cys residues of tau, thereby reducing Sarkosyl-insoluble
tau levels, neuronal death and brain dysfunction in P301L
tau-transgenic mice.
Results
Chemical array screening for tau aggregation inhibitors. To
find an inhibitor of granular tau oligomer formation, we screened
a series of tau-binding compounds, using a small-molecule array
consisting of 6,788 compounds in the RIKEN Natural Products
Depository (NPDepo). This initial screen led to the identification
of 86 compounds displayed the potential to associate with tau.
These compounds were subsequently assayed for thioflavin T
(ThT) binding, with the exclusion of false positives using a pel-
leting assay in which tau was quantified in pellets derived from
ultracentrifugation of a mixture of tau aggregates. Three com-
pounds, epinephrine (Fig. 1a), pyrocatechol violet (Fig. 1b) and
lobaric acid (Fig. 1c), markedly decreased ThT binding (Fig. 1d–f)
and insoluble (aggregated) tau in the pellet fraction (Fig. 1g–i). As
the chemical backbones of epinephrine and pyrocathechol violet
consist of 1,2-dihydroxybenzene (Fig. 1a,b), we hypothesized that
1,2-dihydroxybenzene endows these compounds with the ability
to inhibit tau aggregation.
Inhibition of tau aggregation by 1,2-dihydroxybenzene.
Supporting our hypothesis, we observed dose-dependent
reductions in heparin-induced ThT fluorescence when cell-free
preparations containing recombinant wild-type 2N4R tau
were exposed to a series of 1,2-dihydroxybenzene-containing
compounds. Results are shown for L-3,4-dihydroxyphenylalanine
(Fig. 2a), dopamine (Fig. 2b), norepinephrine (Fig. 2c),
epinephrine (Fig. 2d) and isoproterenol (ISO; Fig. 2e);
adrenochrome, an oxidized form of epinephrine (Fig. 2f), also
reduced ThT fluorescence. Octopamine, a compound with a
1-dihydroxybenzene structure, and 3-methoxytyramine, a
catechol-O-methyltransferase-mediated metabolite of dopamine,
did not alter ThT fluorescence (Fig. 2g,h), verifying the specificity
of the effects produced by the compounds with a 1,2-dihydrox-
ybenzene skeleton. This set of data showed that compounds with
a 1,2-dihydroxybenzene skeleton can inhibit tau aggregation
independently of their oxidation state. Subsequent investigations
focused on ISO, a b1/2 adrenergic receptor agonist that can
cross the blood–brain barrier (BBB)36,37; ISO is indicated for a
number of medical conditions and neither interferes with
neurotransmission nor induces major adverse effects. ISO
treatment of Neuro2A cells engineered to stably express P301L
tau38 results in dose-dependent reductions of SDS-insoluble tau
levels in the absence of alterations in the levels of soluble
tau (Fig. 3a). Importantly, the inhibitory actions of ISO on
tau aggregation were not blocked by pretreatment of P301L
tau-expressing Neuro2A cells with propranolol (1–10 mM), a
competitive antagonist of the b adrenergic receptor (Fig. 3b),
indicating that the inhibitory action of ISO on tau aggregation is
not mediated through b adrenergic receptors.
We subsequently made a detailed examination of
heparin-induced tau aggregates to gain further insight into
the mechanism of action of ISO. Sucrose density gradient
centrifugation demonstrated the absence of filamentous tau in
ISO-treated (100 mM) tau aggregate mixtures (fractions 4–6;
Fig. 4a). This analysis also showed that ISO markedly reduced
granular tau oligomer levels (fraction 3) while increasing
the levels of tau in fractions 1–2 (Fig. 4a). Analysis of
heparin-induced tau aggregates by atomic force microscopy
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(AFM) revealed that ISO treatment leads to a significant
reduction of the number of tau filaments and granular tau
oligomers and an increase in the number of small tau granules
(Fig. 4b). These observations suggest that ISO maintains tau in a
soluble form or limits its conversion to small, amorphous
granules. This interpretation is consistent with our finding that,
under non-reducing conditions, ISO prevents tau molecules from
forming soluble oligomers (Fig. 4c).
Inhibitory mechanism of 1,2-dihydroxybenzene. ISO-coated
magnetic FG (Functional magnetic) beads (Supplementary
Fig. 1) were used to identify the binding site of 1,2-dihydrox-
ybenzene compounds to tau; for this, FG beads were incubated
with tau in the presence (þ ) or absence ( ) of ISO before
elution with either 1M KCl or sample buffer (SB). As shown in
Fig. 5a, tau-ISO complexes could be efficiently ut not KCl, indi-
cating that the protein–drug interaction depends on non-ionic
bonding. Further, we observed that ISO bound monomeric,
dimeric, trimeric and tetrameric forms of tau. Compared with
when ISO was not included in the incubation mixture, FG beads
bound monomeric tau more strongly (14.1-fold) than dimeric tau
(2.2-fold) in the presence of ISO, whereas the amounts of trimeric
and tetrameric tau bonding to the FG beads were not influenced
by ISO (Fig. 5b). Thus, these results demonstrate that ISO pri-
marily associates with monomeric species of tau.
The site at which ISO binds to tau was further explored by
comparing the binding of the drug to wild-type tau and a mutant
form of tau that lacks the microtubule-binding region (DMTBR).
As tau could only be eluted (recovered) when wild-type tau was
used (Fig. 5c), we conclude that ISO binding to tau depends on
the presence of MTBR. More precise information regarding the
ISO-MTBR site of interaction was obtained by pre-treating FG
beads with peptides corresponding to each of the four repeats of
tau (R1–R4) before the addition of the drug and subsequent
recovery of ISO-tau complexes. Such recovery was only possible
from beads that had been pre-treated with vehicle or R1 and R4
peptides (Fig. 5d), indicating that ISO binds to sites localized in
the R2 and/or R3 regions of tau.
The R2 and R3 regions of tau are characterized by cysteine
residues (positions 291 and 322) and hexapeptides (positions
275–280 in PHF6*; positions 306–311 in PHF6); these regions are
critical for tau fibril formation39–41. By testing the ability of ISO to
bind to deletion mutants of tau (DPHF6- and DPHF6*-2N4R tau)
and in mutant forms of tau in which Cys was substituted by Ala
(C291, 322A-2N4R and C322A-2N3R tau), we observed
associations between ISO, DPHF6- and DPHF6*-2N4R tau, but
not C291, 322A-2N4R and C322A-2N3R tau (Fig. 5e); this
demonstrated that ISO binds Cys residues in tau. Based on this
and other results reported above, we propose that
1,2-dihydroxybenzene non-ionically binds Cys residues in the
MTBR and thus inhibits the formation of tau oligomers by
occluding intermolecular tau interactions. We next used mass
spectrometry to confirm that 1,2-dihydroxybenzene binds Cys
residues in tau; for this, a partial Cys-containing peptide of tau, R3’
(skvtskcgslgn; molecular weight (MW)¼ 1,180.3), was analysed
after incubation with either the vehicle or the 1,2-
dihydroxybenzene-containing compounds, ISO (MW¼ 211.3)
and pyrocatechol (MW¼ 110.1). Incubation of the R3’ peptide
with the vehicle yielded two peaks (m/z¼ 1,180.5 and 2,358.0),
corresponding to peptide monomers and dimers (Fig. 6a);
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Figure 1 | Identification of tau aggregation inhibitor. Epinephrine (a,d,g), pyrocatechol violet (b,e,h) and lobaric acid (c,f,i) were screened as tau
aggregation inhibitors. Inhibitory effects of tau aggregation were determined by fluorescence of thioflavin T (d,e,f) and pelleting assay (g,h,i) of
heparin-induced tau polymerization incubated with various concentrations of compounds (1, 10 and 100mM). Dimethyl sulfoxide was used as the vehicle.
Thioflavin T fluorescence was measured at the indicated time, and results were represented as percentage of maximum thioflavin T fluorescence
(d,e,f;mean±s.d. of triplicate experiments; n¼ 3).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10216 ARTICLE
NATURE COMMUNICATIONS | 6:10216 | DOI: 10.1038/ncomms10216 | www.nature.com/naturecommunications 3
as well as peaks corresponding to the R3’ peptide monomers
and dimers (Fig. 6b and Supplementary Table 1). Peak shifts
(m/z¼ 1,180.6-1,288.5) were also detected after incubation with
pyrocatechol (Fig. 6c and Supplementary Table 1), but not with
octopamine, a 1-hydroxybenzene containing compound (Fig. 6d).
No peak shifts were observed when a mutant Cys-Ala R3’ peptide
(skvtskagslgn; MW¼ 1,148.2) was incubated with the vehicle
(Fig. 6e), ISO (Fig. 6f), pyrocatechol (Fig. 6g) or octopamine
(Fig. 6h). Together, these analyses confirmed that ISO could block
tau aggregation through interaction of its 1,2-dihydroxybenzene
group with Cys residues in tau.
Effects of ISO in an animal model of tauopathy. To investigate
the efficacy of ISO in inhibiting tau aggregation and subsequent
neuronal loss in a relevant animal model of tauopathy, we used a
transgenic mouse line that expresses a highly aggregating form of
tau, encoded by the human P301L tau gene. Studies were per-
formed in aged mice (17–18 months) as the amount of Sarkosyl-
insoluble tau aggregate in the brain increases with age26. Animals
(non-transgenic controls and P301L tau transgenic mice) received
DL-ISO in their chow at dose of 1.5mg g 1 chow; food intake and
body weight did not change over the duration (3 months) of
treatment (Supplementary Fig. 5). The oral DL-ISO regimen did
not alter TBS-soluble levels of tau, but significantly reduced the
load of Sarkosyl-insoluble tau in the cortex (26.1±14.5%; n¼ 12),
P¼ 0.01482 (unpaired Welch’s t-test), Fig. 7a) and hippocampus
(36.7±28.3% (n¼ 8), P¼ 0.03174 (unpaired Student’s t-test)
Fig. 7b), as compared with mice fed the control diet. Appropriate
drug dosage was established in pilot studies in wild-type mice;
following administration of ISO at 1.5mg g 1 chow for 2 weeks,













































































































































Figure 2 | Inhibitory effects of 1,2-dihydroxybenzene-containing compounds and their derivative compounds on tau aggregation. Thioflavin T-binding
activity was dose-dependently inhibited by L-3,4-dihydroxyphenylalanine (a), dopamine (b), norepinephrine (c), epinephrine (d) and isoproterenol
(e) (1,2-dihydroxybenezene; black dotted square), and adrenochrome (f) (o-quinone; black dotted circle), but not by octopamine (h) (1-hydroxybenzene;
grey dotted circle) or 3-methoxythylamine (g) (1-hydroxy-2-methoxybenzene; grey dotted square). Results are shown as percentage of maximum
fluorescence (mean±s.d. of triplicate experiments; n¼ 3).
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respectively. Potential mediation of the actions of ISO by b1/2
adrenergic receptors was precluded because similar reductions of
Sarkosyl-insoluble tau were observed in both cerebral cortex
(Fig. 7c) and hippocampus (Fig. 7d) when P301L tau-transgenic
mice were fed for 3 months with the D-isomer of the drug
(1.5mg g 1 chow), which lacks adrenergic activity (cf. Fig. 7a,b,
respectively). In addition, administration of the inactive isomer of
ISO for 2 months resulted in dose-dependent reductions of
Sarkosyl-insoluble tau (Fig. 7e). The latter two observations
indicate that the ability of D/DL-ISO to inhibit tau aggregation are
dose- and time-dependent.
Our previous observations that aged P301L tau-transgenic mice
display neuronal loss in the entorhinal cortex, temporal lobe and
amygdala26 were reproduced in the present study (Fig. 7f–h).
Having previously attributed these effects to the increased levels of
insoluble Sarkosyl-insoluble (aggregated) tau in the brains of aged
P301L tau-transgenic mice26, we hypothesized that ISO would
promote neuronal survival by reducing tau aggregation. Our
hypothesis was supported by the results depicted in Fig. 7f–h,
where ISO (1.5mgg 1 chow for 3 months) is seen to prevent age-
related reductions in neuron numbers in the entorhinal cortex,
temporal lobe and basolateral amygdala of aged P301L tau-
transgenic mice; the drug did not influence neuron numbers in any
of these areas in non-transgenic mice.
On the basis of above findings, we suggest that inhibition of tau
aggregation via ISO-capping of Cys residues of tau prevents the
aggregation of toxic tau and therefore, neuronal loss. Such a
mechanism is supported by the observation that D-ISO
(15mg g 1 chow) reduces Sarkosyl-insoluble tau and blocks
neuronal loss in the hippocampus of PS19 mice (a model of
tauopathy which also displays severe hippocampal neuronal
loss20); the latter conclusion is supported by the magnetic
resonance imaging data presented in Supplementary Fig. 2.
Although the neuronal loss observed in P301L tau-transgenic
mice was not accompanied by significantly impaired spatial
memory in the Morris water maze test26, they displayed
significantly reduced locomotor activity during the first minute
of placement in an open field arena (Fig. 7i). On the other hand,
their locomotor activity over 30min in the open field arena did
not differ from that observed in non-transgenic mice (Fig. 7j);
these observations suggest that P301L tau-transgenic mice exhibit
emotional disturbance without any change in overall motor
activity. Interestingly, ISO alleviated the emotional disturbance in
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Figure 3 | Isoproterenol inhibits tau aggregation independent of b adrenergic stimulation in cultured cells. Neuro-2a cells expressing human 2N4R tau
(P301L) were treated with 0 (milliQ water), 0.01, 0.1 and 1 mM isoproterenol, 10mM lithium chloride as a positive control as an inhibitor of glycogen
synthase kinase and 10mM sodium chloride as a negative control for 48 h. SDS-insoluble (a, upper part of panel) and RIPA-soluble fractions (a, middle part
of panel) were obtained from the cell homogenates and were subjected to immunoblot analysis with JM antibody that recognized total tau.
Immunoreactivity was quantified (a, lower part of panel), and levels of SDS-insoluble tau were normalized by corresponding RIPA-soluble tau. Results are
represented as percentage of control (mean±s.d. of 3–6 experiments; 10mM sodium chloride (n¼ 3), 10mM lithium chloride (n¼4), vehicle (n¼ 6),
0.01mM isoproterenol (n¼ 5), 0.1mM isoproterenol (n¼ 5), 1mM isoproterenol (n¼ 5)). ***Po0.001; ****Po0.0001 (one-way analysis of variance
(ANOVA), with Tukey’s multiple comparisons test). (b) Neuro-2a cells expressing human 2N4R tau (P301L) were pretreated with 0, 1 and 10mM
propranolol 30min before treatment with 0 (milliQ water), 1 mM isoproterenol, 10mM lithium chloride and 10mM sodium chloride for 48 h. SDS-insoluble
(b, upper part of panel) and RIPA-soluble (b, middle part of panel) fractions were obtained and subjected to immunoblot using JM antibody.
Immunoreactivity was quantified (b, lower part of panel) and levels of SDS-insoluble tau were normalized to corresponding RIPA-soluble tau. Results are
represented as percentage of control (mean±s.d. of 2–3 experiments; 10mM sodium chloride (n¼ 2), 10mM lithium chloride (n¼ 2), vehicle (n¼ 3), 1mM
propranolol (n¼ 2), 10mM propranolol (n¼ 2), 1mM isoproterenol (n¼ 3), 1mM propranolol/1mM isoproterenol (n¼ 3), 10 mM propranolol/1mM
isoproterenol (n¼ 3)). ***Po0.001 (one-way ANOVA, with Tukey’s multiple comparisons test). ISO, isoproterenol; Pro, propranolol.
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Discussion
Growing evidence for the key role of aggregates of tau protein in
AD and FTDP-17 has spurred efforts to explore pharmacological
means to maintain tau in its soluble form and thus, to prevent its
aggregation.
ISO was identified as a potential inhibitor of tau aggregation
after screening a library of small molecules. Detailed analysis
revealed that the drug acts by binding Cys residues in tau that
prevent tau oligomerization and formation of insoluble tau
aggregates. This property of ISO is attributed to the two phenolic
hydroxyl groups in the 1,2-dihydroxybenzene backbone, as other
compounds sharing this structure (L-3,4-dihydroxyphenylalanine,
dopamine, norepinephrine, epinephrine, and ISO), as well as
1,2-dihydroxybenzene itself, also inhibit tau aggregation, albeit
to lesser extents and/or ability to easily traverse the BBB. The pre-
requisite role of the 1,2-dihydroxybenzene backbone structure is
illustrated by the inability of octopamine and 3-methoxytyramine
or 3-methoxy-4-hydroxyphenethylamine, whose chemical back-
bones include 1-hydroxybenzene, to inhibit tau aggregation. Given
that ISO is subject to oxidation, our finding that o-quinone
(adrenochrome) inhibit tau aggregation as effectively as
epinephrine (its non-oxidized parent molecule) is important
because it demonstrates that the inhibitory actions of
1,2-dihydroxybenzene-containing compounds on tau aggregation
do not depend on their oxidative status. Interestingly, previous
work demonstrated nucleophilic covalent attachment of the
o-quinone in 1,2-dihydroxybenzene compounds to the
sulfate group in Cys42,43; consistent with this finding. It would
therefore appear that oxidized 1,2-dihydroxybenzene-containing
compounds and their o-quinone forms bind covalently to the
sulfate group of Cys; this view is plausible because we found that
the ISO-bound tau bond cannot be broken eluted by 1M KCl. The
site of chemical reaction between Cys residue of tau and
o-quinone would be regulated by steric and electronic
interactions of these two compounds. Further, MS analysis
revealed that complexes comprised of a partial tau R3’ peptide
and ISO include two phenolic hydroxyl groups, but not
o-quinone. As shown in the schema in Supplementary Fig. 3,
quinone binding to the sulfate group of Cys in tau will be followed
by electron transfer to quinone and its back-conversion into ISO
(personal communication, M.S. and H.K.)44. Oxidation during tau
aggregation leads to increased disulfide bonding between Cys
residues in tau45,46; however, substitution of Cys to Ala in tau
(C291, 322A-2N4R tau) can induce tau aggregation, suggesting
that capping of Cys residues of tau by 1,2-dihydroxybenzene
precludes the formation of toxic tau aggregates by hindering
disulfide bonding and formation of tau oligomers (Supplementary
Fig. 4a,b). The aggregation of wild-type tau was significantly
attenuated by both 10 and 100mM of ISO, whereas that of C291,
322A-2N4R tau was only inhibited by the higher dose of ISO
(Supplementary Fig. 4c). Besides showing that ISO binds the Cys
residue of tau, this observation indicates that ISO also affects
PHF6((306) VQIVYK(311))41,47 binding, and thus increasing the
propensity to form b-sheets and inhibiting the formation of seeds
for the aggregation of toxic tau.
It deserves mention that, although NFTs themselves do not
exert toxic actions25, the degree of dementia correlates well with
NFT number and the extent of neuronal loss13,14. Accordingly,
the irreversible brain dysfunction observed in dementia may be
ascribed to the neuronal loss that follows the aggregation of toxic
tau. Support for this view comes from our finding that ISO
reverses emotional disturbances associated with the expression of
P301L tau (Fig. 7i) and stimulates neural activity in the prelimbic
frontal cortex (Supplementary Fig. 6a); the latter is accompanied
by contemporaneous reductions in the levels of Sarkosyl-
insoluble tau in the prelimbic cortex (Supplementary Fig. 6b).

































































































Figure 4 | Inhibition of tau oligomer formation by isoproterenol.
Heparin-induced tau aggregation mixture (120 h incubation) was
subjected to sucrose density gradient centrifugation (a) and AFM
observation (b). Tau aggregation mixture was separated into six fractions,
and levels of tau in each fraction were analysed by western blot using
tau5 antibody that recognized total tau. In AFM observation, three
images were obtained from different areas (2 2 mm2) of the mica and the
number and size of tau aggregates was quantitated using the image
analysis programme, Matlab. Sizes of tau aggregates are 0–9.9 nm
(arrowhead), 10.0–19.9 nm (arrow), 20.0–39.9 nm (black solid circle),
40.0–79.9 nm (black dotted circle) and not less than 80nm (black
solid square). Results represented as mean±s.d. of three experiments
(n¼ 3; b, lower panel). **Po0.01; ***Po0.001; ****Po0.0001 (unpaired
Student’s t-test). In first 60min of heparin-induced tau aggregation, higher
order tau oligomer was formed in soluble fraction with longer incubation
time (c, vehicle), but growth of tau oligomer was not seen in the presence
of isoproterenol (c, ISO). Tau oligomer in soluble fraction was detected by
non-reducing condition using tau5 antibody.
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In summary, we have demonstrated that ISO, a drug that
penetrates the BBB, efficiently inhibits the formation of
Sarkosyl-insoluble tau in a mouse line carrying an aggressive
mutant form of tau (P301L); the P301L mutation is responsible
for FTDP-17, and mice expressing it are very prone to tau
aggregation and neuronal death. Our results point to the potential
of 1,2-dihydroxybenzene-based compounds to prevent and delay
tauopathies such as FTDP-17 and AD by preventing neuronal
dysfunction and loss restoring behavioural homeostasis. Using a
variety of analytical approaches, we propose that the therapeutic
efficacy of 1,2-dihydroxybenzene-containing compounds hinges
on their ability to hinder intermolecular interactions between tau
molecules by binding to the Cys residues of tau. No untowards
reactions to chronic (3 month) ISO exposure were observed in
this study; further, oral administration of the pharmaceutical
PROTERENOL S (0.25mg kg 1) to cynomologus monkeys for 8
weeks was not accompanied by adverse effects (unpublished
observations). Nevertheless, the caveat that toxicity might result
from covalent modification of Cys residues in other proteins must
be considered during subsequent development of ISO-related
compounds for therapeutic use. On the other hand, it should be
noted that ISO is commonly prescribed for conditions such as
asthma and bradycardia, with the therapeutic dosages in humans
being almost fivefold those that we found to be effective for
disrupting tau aggregation in mice48. The present work suggests a
promising novel therapeutic target in the management of
tauopathies; its screening strategy and description of a series of
compounds that display nucleophilie for Cys residues in tau49,
provide an important lead in this respect.
Methods
Materials. Six-thousand seven-hundred eighty-eight small molecular compounds
were obtained from the RIKEN Natural Products Depository (NPDepo) and
dissolved in dimethyl sulfoxide to obtain a stock solution (10mM or 10mgml 1).
The polyclonal anti-total tau antibody (JM) was prepared as previously
described50. The monoclonal anti-total tau antibody (tau5) was purchased from
α tau blot
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e
Figure 5 | Identification of isoproterenol (ISO)-binding site on tau. ISO and tau binding were performed according to the protocol described in
Supplementary Fig. 1 and ISO-bound tau was recovered in KCl, SB and Pel. Each fraction was subjected to immunoblot analysis with tau5 antibody (a). In SB
fraction, tau monomer and oligomer were detected from an eluate of FG beads with ISO (ISO (þ )) and without ISO (ISO ( ); b, left part of panel). Levels of
tau monomer and oligomer were quantified (b, right part of panel) and shown as mean±s.d. (triplicate experiments; n¼ 3). *Po0.05; ****Po0.0001
(unpaired Student’s t-test). FG beads with ISO (ISO (þ )) and without ISO (ISO ( )) were reacted with DMTBR-tau. Tau was not recovered in SB fraction
(c). Pretreated ISO with R1 (tapvpmpdlknvkskigstenlkhqpgggk), R2 (vqiinkkldlsnvqskcgskdnikhvpgggs), R3 (vqivykpvdlskvtskcgslgnihhkpgggq) and R4
(vevksekldfkdrvqskigsldnithvpgggn) peptides was incubated with wild-type (WT) 2N4R tau. Pretreated IS0 with R2 and R3 could not bind to tau, but R1 and
R4 pretreatment could bind (d). C291, 322A-2N4R tau and C322A-2N3R tau did not show tau band as well as tau incubating beads without ISO, ISO (þ ), but
WT 2N4R tau, DPHF6-tau and DPHF6*-tau showed tau band as ISO-bound tau (e). MTBR, microtubule-binding domain repeat.
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Invitrogen. All other reagents were of analytical grade and purchased from
Nacalai Tesque Inc., Sigma-Aldrich Corp. and WAKO Pure Chemical
Industries.
Chemical array screening. The method is based on identification of associations
between a protein of interest with a library of candidate chemicals. In this study,
the array consisted of 6,788 small-molecule compounds (RIKEN Natural Products
Depository, NPDepo) immobilized under ultraviolet radiation on to photo-affinity
linker-coated glass slides; the assay was performed using a previously reported
method51–53 with slight modifications. Briefly, after blocking with 1% skimmed
milk in 10mM HEPES/100mM NaCl for 1 h at room temperature, the slides were
treated with recombinant tau protein in 10mM HEPES/100mM NaCl/0.05%
Tween for 16 h at 4 C. The slides were then probed with anti-tau antibody (JM) for
4 h, followed by incubation with a Alexa 633-labelled secondary antibody for 1 h at
room temperature. Signal detection was performed with a GenePix 4100A
microarray scanner (Molecular Devices), equipped with a 635-nm laser and
655–695 nm band-pass emission filter. When Fraction 1 (soluble tau) was used as
bait, 86 out of 6,788 compounds showed potential association with tau. In contrast,
none of the compounds tested showed associations either Fraction 3 (granular tau
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Figure 6 | Binding of 1,2-dihydroxybenzene-containing compounds with Cys residue of tau by mass spectrometry analysis. Vehicle (milliQ water; a) and
1-hydroxybenzene-containing octopamine (OCT; MW¼ 153.2; d) were used as negative controls. Compounds containing 1,2-dihydroxybenzene
isoproterenol (ISO; MW¼ 211.3; b) and pyrocatechol (CAT; MW¼ 110.1; c) incubated with tau R3 partial peptide, R3’ (skvtskcgslgn; MW¼ 1,180.3) showed
ISO/R3’ and CAT/R3 signal in mass spectrum (b,c). Mutant C-A R3’ peptide (skvtskagslgn; MW¼ 1,148.2; e–h) incubated with vehicle (e), ISO (f), CAT
(g) and OCT (h) only showed mutant R3’ signal. Data are normalized to the each maximum mass spectrometry signal.
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Figure 7 | Inhibition of tau aggregation and neuronal loss by isoproterenol (ISO) in vivo. Mice expressing human 2N4R tau (P301L) and non-transgenic
(Tg) littermate were administrated with vehicle, 1.5mg ISO (a,b,f-j) and D-ISO (c,d) per g chow for 3 months. The mice were treated with 1.5–7.5mg D-ISO per
g chow for 2 months (e). In the cerebral cortex (a,c) and hippocampus (b,d,e), levels of Sarkosyl-insoluble and TBS-soluble tau were analysed by western blot
and quantified. JM antibody that recognized total tau was used for detection. Densitometry of tau immunoreactivity was quantified and intensity levels of
Sarkosyl-insoluble tau normalized to that of TBS-soluble tau. Results are shown as percentage of control (mean±s.d. of 3–12 samples from 3–8 mice from
three repeated independent experiments). *Po0.05; **Po0.01 (unpaired Welch’s (a) and Student’s t-tests (b-e)). Coronal sections (4-mm) of mice
administrated the vehicle and ISO for 3 months were stained with cresyl violet. The number of neurons in entorhinal cortex (f), temporal area (g) and
basolateral amygdala (h) were counted under a microscope assisted with the Neurolucida tracing system. Results are shown as mean±s.d. of 5–13 samples
from 3–5 mice from two independent experiments. *Po0.05; **Po0.01 (one-way analysis of variance (ANOVA), with Tukey’s multiple comparisons test).
Locomotor activity in ISO-treated and untreated mice was monitored in an open field arena (50 5040cm3) as described in the Methods. Velocity over
the 1st minute (i) or 30th minute of testing (j) was determined by computing the time intervals between sequential positions of the mice in each video frame.
Results are shown as mean±s.d. of 6–10 mice. *Po0.05 (one-way ANOVA, with Tukey’s multiple comparisons test). Sample sizes in each experiment are
presented in each figure, and mice numbers are described in Supplementary Table 2. fr, fraction.
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Preparation of recombinant tau protein. Various human tau cDNA was con-
structed in a pRK172 vector based on the longest form of human wild-type tau
encoded 441 amino acid (2N4R); deletion of amino acids at positions 252 to 376
(DMTBR), positions 306 to 311 (DPHF6), positions 275 to 280 (DPHF6*) and with
substitutions at C291A and C322A (C291, 322A). A construct that encoded 2N3R
tau with a mutation at C322A (2N3R-C322A) was produced. Each recombinant tau
was expressed in Escherichia coli BL21 (DE3) and purified by modified method
reported previously33. After E. coli expressing tau was sonicated and boiled,
recombinant tau proteins in the heat-stable fraction was purified by ion-exchange
chromatography (P11; GE Healthcare, or Cellufine Phosphate; JNC Corp.),
ammonium sulfate fractionation, gel filtration chromatography (NAP10 column;
GE Healthcare) and reverse phase-HPLC (COSMOSIL Protein-R Waters; Nacalai
Tesque Inc.). After freeze-drying, recombinant tau proteins were dissolved in
milliQ water and stored at  80 C as a stock solution.
ThT assay. ThT binding was measured with modified method reported
previously33. Recombinant wild-type 2N4R tau (10mM), compounds (indicated
concentration) and ThT (10 mM) were mixed in the HEPES buffer (10mM HEPES,
pH¼ 7.4; 100mM NaCl), and incubated with heparin (0.06mgml 1; Acros
Organics) at 37 C. At specific time points, fluorescence generated by the binding of
ThT to tau aggregates was measured (excitation wavelength: 444 nm; emission
wavelength: 485 nm). The tau aggregation mixture was collected 120 h after
incubation, and analysed with a pelleting assay, sucrose density gradient
centrifugation or AFM.
Sucrose density gradient centrifugation. Sucrose density gradient centrifugation
was performed as described previously33. Tau aggregation mixture (1ml) was
layered on top of sucrose step gradients (each 1ml of 10, 20, 30, 40 and 50%
sucrose in HEPES buffer (pH¼ 7.4)) was centrifuged (50,000 r.p.m., 2 h) in a
MLS50 rotor (Beckman Coulter) and separated into fractions. Pellet (Pel; Fraction
6) was suspended in 1ml of buffer containing HEPES buffer, and the recovered tau
in each fraction was evaluated with western blotting.
Pelleting assay. Pelleting assay was performed by modified method reported
previously54. After ThT assay, samples including tau aggregates were centrifuged
(70,000 r.p.m., 2 h) in TLA100.4 or TLA110 rotors (Beckman Coulter) and
separated into supernatant and pellet. After the pellet was suspended and sonicated
in Laemmli SB including 2-mercaptoethanol, they were boiled for 5min.
Cell culture. Neuro2A cell line stably expressing myc-tagged tau (P301L) was
established according to a previously described method38. Cells were cultured in
Dulbecco’s Modified Eagle’s medium supplemented with 10% fetal bovine serum,
50mgml 1 gentamicin, 5 mgml 1 puromycin and 1mgml 1 G418 at 37 C
under 5% CO2. Cells at 80–90% confluency were plated in mediums without
puromycin and G418. Cells were treated with ISO (0.01, 0.1 and 1 mM), lithium
chloride (10mM) as a positive control that is a glycogen synthase kinase inhibitor,
or sodium chloride (10mM) as a negative control. To confirm the relationship
between tau aggregation with b adrenergic effect by ISO, cells were treated with
1 mM ISO, 30min after pretreating with or without 1 or 10 mM propranolol, which
is a competitive adrenergic b blocker. Cells were sonicated in modified RIPA buffer
containing 50mM Tris (pH¼ 7.4), 1% NP-40, 0.25% sodium deoxycholate,
150mM NaCl, 1mM ethylene glycol tetraacetic acid (EGTA), protease
inhibitors (5 mgml 1 pepstatin, 5 mgml 1 leupeptin, 2 mgml 1 aprotinin and
0.5mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride), and
phosphatase inhibitors (1mM okadaic acid, 1mM Na3VO4 and 1mM NaF) 48 h
after treatment. The lysates (1ml) were layered onto 0.32M sucrose containing
10mM Tris (pH¼ 7.4), 0.8M NaCl and 1mM EGTA, and centrifuged
(15,000 r.p.m., 10min, 4 C) in an ARO15–24 rotor (Tomy Seiko). The upper part
(1ml) was transferred to 1.5-ml tubes (357448; Beckman Coulter), centrifuged
(50,000 r.p.m., 30min, 4 C) in a TLA55 rotor (Beckman Coulter) and separated
into supernatant (RIPA-soluble fraction) and pellet. After the pellets were
sonicated in 1% SDS/RIPA and 1% SDS/TBS buffers, they were centrifuged
(50,000 r.p.m., 1 h, 4 C) in a TLA55 rotor and separated into supernatant and
pellet. Pel (SDS-insoluble fraction) was dissolved in 70% formic acid and air-dried.
Samples from RIPA-soluble and SDS-insoluble fractions were dissolved in Laemmli
SB including 2-mercaptoethanol, and then boiled for 5min.
AFM observation. Morphology of the recombinant tau aggregate was observed
under AFM33. After ThT assay, samples including tau aggregates were loaded to
mica and incubated at room temperature for 30min in a moist box. The mica was
washed with milliQ water and then cantilever (OMCL-TR400PSA; Olympus)
detected tau aggregate with 3D-Stand Alone AFM (Asylum Research) under the
tapping mode. Major and minor axis of tau aggregates and the number of tau
aggregates were determined by image analysis using Matlab-based software
(MathWorks Co. Ltd.).
Tau oligomerization assay. After recombinant wild-type 2N4R tau protein
(10 mM), and ISO (100 mM) or methylene blue (100 mM) mixing with buffer
containing HEPES (10mM, pH¼ 7.4) and NaCl (100mM), heparin sulfate
(0.06mgml 1) was added, and incubated at 37 C. In each time point 10–60min,
tau aggregation mixture were collected and dissolved in Laemmli SB
without 2-mercaptoethanol. Tau protein in the samples was separated in
SDS–polyacrylamide gel electrophoresis gel without dithiothreitol buffer and
visualized in western blotting (Figs 4c and 5).
Binding assay with FG beads. To determine binding of tau and ISO, we prepared
Streptavidin FG beads (5mgml 1; Tamagawa Seiki) reacted with biotinylated ISO
(62.5 mM; Supplementary Fig. 1A), and Streptavidin FG beads (5mgml 1) reacted
with biotin (62.5 mM) as a negative control. Avidin-biotin complexes were formed
by incubation for 1 h at 4 C. After recombinant wild-type 2N4R tau (0.6 mM;
input) was reacted with the complexes by rotation (4 h at 4 C), they were cen-
trifuged and separated into pellet and supernatant. After washing the pellet with
100mM KCl buffer (pH 7.4) thrice, the pellet was suspended and incubated in 1M
KCl solution for 5min on ice. The suspension was centrifuged, the supernatant
(KCl) was analysed, or the pellet was suspended in Laemmli SB without 2-mer-
captoethanol, incubated for 15min at 60 C and separated into Pel and supernatant
(SB; Supplementary Fig. 1b). The Input, KCl and Pel were solubilized or resus-
pended in Laemmli SB. Tau protein in the samples was detected with western
blotting. To determine binding region, R1 (tapvpmpdlknvkskigstenlkhqpgggk), R2
(vqiinkkldlsnvqskcgskdnikhvpgggs), R3 (vqivykpvdlskvtskcgslgnihhkpgggq) or R4
(vevksekldfkdrvqskigsldnithvpgggn) peptides (120 mM) were pretreated with the
avidin-biotin complexes before incubation with recombinant wild-type 2N4R tau.
MASS spectrometry. Recombinant R3’ (skvtskcgslgn) and mutant Cys- Ala R3’
(skvtskagslgn) peptides (10 mM) were incubated with compounds (100 mM) for 5
days at 37 C. The samples were diluted 20 times with milliQ water and loaded to
spot under presence of a-Cyano-4-hydroxycinnamic acid (10mgml 1). After
drying, the samples were analysed using 4800 plus MALDI Tof/Tof analyzer
(Applied Biosystems).
Animals. Transgenic mice expressing 2N4R tau (P301L) with myc- and flag-tag at
N- and C-terminal under CaM kinase II promoter was created previously26. Male
P301L tau-transgenic mice 17- to 18-month old were treated with ISO or D-ISO
(1.5–7.5mg g 1 chow) for 2 or 3 months. The numbers of animals used in each
experiment are indicating in Supplementary Table 2. All experimental procedures
used in this study were approved by the Committee of Animal Experiments at the
National Center for Geriatrics and Gerontology.
Tissue extraction. P301L tau-transgenic mice were anaesthetized and killed after
treatment with the compounds; the hippocampus and cerebral cortex were
collected. The tissues were homogenized in TBS buffer containing 50mM Tris
(pH¼ 7.4), 150mM NaCl, 1mM EGTA, 1mM EDTA, protease inhibitors and
phosphatase inhibitors. The homogenates were centrifuged (23,000 r.p.m., 15min,
4 C) in a TLA55 rotor and separated into supernatant (TBS-soluble fraction) and
pellet. Pellets were resuspended in 0.32M sucrose containing 10mM Tris (pH 7.4),
0.8M NaCl and 1mM EGTA and centrifuged (23,000 r.p.m., 15min, 4 C) in a
TLA55 rotor. Supernatants were collected and treated with 1% Sarkosyl for 1 h at
37 C. They were centrifuged (60,000 r.p.m., 1 h, 4 C) in a TLA100.4 or 110 rotors
and separated into supernatant and pellet (Sarkosyl-insoluble fraction). Samples
from TBS-soluble and Sarkosyl-insoluble fractions were dissolved in Laemmli SB
including 2-mercaptoethanol, and then boiled for 5min.
Count of neuronal cells. Number of neuronal cells in the brain was measured with
modified method reported previously26. After P301L tau-transgenic mice were
anaesthetized and transcardially perfused with 10% formalin, brains were fixed in
10% formalin solutions for 48 h. Coronal sections (4 mm) were produced from
brains embedded by paraffin, and stained with cresyl violet. We counted the
number of neuronal cells in the sections using microscope linked to a Neurolucida
tracing system (MicroBrightField Inc.).
Western blotting. Samples dissolved in Laemmli SB were separated by Novex
3–8% Tris-Acetate Gel (binding assay and tau oligomerization assay; Invitrogen) or
SuperSep Ace 5–20% gel (other assays; WAKO Pure Chemical Industries) and
transferred onto membranes with semi-dry transfer systems (Bio-Rad Laboratory).
The membrane was blocked with 5% milk in PBS-T for 1 h at room temperature.
They were probed with antibodies overnight at 4 C. After washing the membrane
with PBS-T, blots were incubated with horseradish peroxidase-linked second
antibodies and then examined by enhanced chemiluminescence detection on
Las3000 or Las4000 (GE Healthcare).
Open field test. Mice were placed in the centre of an open field apparatus
(50 50 40 cm3; O’Hara Co., Ltd.), and their locomotor activity was monitored
with a CCD camera; digital data of real-time images were recorded using the public
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domain NIH Image J software (http://rsb.info.nih.gov/nih-image/). Images were
sampled at 2Hz. Data were analysed using customized Matlab-based software,
using an image analysis tool box (Mathworks Co. Ltd.). During testing, the
sequential position of the mouse was determined in each video frame from which
locomotor speed was calculated.
Mn-enhanced magnetic resonance imaging. Mn-enhanced MRI was performed
as previously described55. Mice were given an intraperitoneal injection of 30mM
MnCl2 (100 mmol kg 1) and returned to their home cages. After 1 h, mice were
exposed successively to three different novel places separated by a small (diameter,
30 cm; height, 30 cm) and big (diameter, 60 cm; height, 30 cm) transparent plastic
wall and was allowed to explore for 120min. Thereafter, mice were returned to
their home cages for 1 h before being anaesthetized with isoflurane (0.5–1.5% in
air) and placement in a Bruker 3T MR scanner; during scanning, breathing and
depth of anaesthesia was continuously monitored, with breathing rate maintained
at 80–100 breaths per min. Mn-enhanced MRI images were visualized with
open-source Osirix software (version 2.5) that allowed navigation through
multidimensional DICOM images; relative regional brain activity was determined
by measuring MR signal intensities, normalized to the mean signal intensity in the
dorsal striatum.
Measurement of ISO levels in the blood and brain. Male C57BL/6J mice (n¼ 7)
were administered ISO (1.5mg g 1 chow) for 2 weeks before sacrifice when blood
plasma and whole brain were collected. The samples were deproteinized using
acetonitrile before determination of ISO concentrations using an LC-MS instru-
ment (UPLC/Quattro Premier XE; Waters).
Statistical analysis. Data are expressed as means±s.d. The significance of dif-
ferences between two groups was assessed by Student’s or Welch’s t-tests, and
differences between multiple groups were assessed by one-way analysis of variance
and Tukey’s multiple comparisons test, using PRISM4 (GraphPad Software Inc.).
Po0.05 was considered statistically significant.
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